BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buil JB, van Zanten ARH, Bentvelsen RG, Rijpstra TA, Goorhuis B, van der Voort S, Wammes LJ, Janson JA, Melchers M, Heusinkveld M, Melchers WJG, Kuijper EJ, Verweij PE. Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021. Euro Surveill 2021;26. [PMID: 34114540 DOI: 10.2807/1560-7917.ES.2021.26.23.2100510] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Muthu V, Rudramurthy SM, Chakrabarti A, Agarwal R. Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World. Mycopathologia 2021. [PMID: 34414555 DOI: 10.1007/s11046-021-00584-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Mohammadi F, Badri M, Safari S, Hemmat N. A case report of rhino-facial mucormycosis in a non-diabetic patient with COVID-19: a systematic review of literature and current update. BMC Infect Dis 2021;21:906. [PMID: 34479495 DOI: 10.1186/s12879-021-06625-3] [Reference Citation Analysis]
3 Benhadid-Brahmi Y, Hamane S, Soyer B, Mebazaa A, Alanio A, Chousterman B, Bretagne S, Dellière S. COVID-19-associated mixed mold infection: A case report of aspergillosis and mucormycosis and a literature review. J Mycol Med 2021;32:101231. [PMID: 34864498 DOI: 10.1016/j.mycmed.2021.101231] [Reference Citation Analysis]
4 Yasmin F, Najeeb H, Naeem A, Dapke K, Phadke R, Asghar MS, Shah SMI, De Berardis D, Ullah I. COVID-19 Associated Mucormycosis: A Systematic Review from Diagnostic Challenges to Management. Diseases 2021;9:65. [PMID: 34698143 DOI: 10.3390/diseases9040065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Zautner AE, Frickmann H, Podbielski A. Risk Assessment for Molds in the Vicinity of a Child Requiring Peritoneal Dialysis Living in a Rural Northern German Area. Microorganisms 2021;9:2292. [PMID: 34835418 DOI: 10.3390/microorganisms9112292] [Reference Citation Analysis]
6 Zhou Y, Liao X, Song X, He M, Xiao F, Jin X, Xie X, Zhang Z, Wang B, Zhou C, Kang Y, Zhang W. Severe Adaptive Immune Suppression May Be Why Patients With Severe COVID-19 Cannot Be Discharged From the ICU Even After Negative Viral Tests. Front Immunol 2021;12:755579. [PMID: 34867988 DOI: 10.3389/fimmu.2021.755579] [Reference Citation Analysis]
7 Casalini G, Giacomelli A, Ridolfo A, Gervasoni C, Antinori S. Invasive Fungal Infections Complicating COVID-19: A Narrative Review. J Fungi (Basel) 2021;7:921. [PMID: 34829210 DOI: 10.3390/jof7110921] [Reference Citation Analysis]
8 Crone CG, Helweg-Larsen J, Steensen M, Arendrup MC, Helleberg M. Pulmonary mucormycosis in the aftermath of critical COVID-19 in an immunocompromised patient: Mind the diagnostic gap. J Mycol Med 2021;32:101228. [PMID: 34826672 DOI: 10.1016/j.mycmed.2021.101228] [Reference Citation Analysis]
9 Roudbary M, Kumar S, Kumar A, Černáková L, Nikoomanesh F, Rodrigues CF. Overview on the Prevalence of Fungal Infections, Immune Response, and Microbiome Role in COVID-19 Patients. J Fungi (Basel) 2021;7:720. [PMID: 34575758 DOI: 10.3390/jof7090720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]